Astragaloside IV: a potential nemesis for gastric cancer
Gastric cancer (GC), a life-threatening malignancy with profound global health impacts, remains a cardinal focus of biomedical research. Recently, astragaloside IV (AS-IV), a bioactive triterpenoid saponin derived from Astragalus mongholicus Bunge, has garnered substantial attention for its multifac...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1636341/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849430281266659328 |
|---|---|
| author | Chao Hu Qiong Li Song-Nan Gong Xiao-Jie Zou Jia-Yue Xu Hai-Feng Ying Lan Zheng |
| author_facet | Chao Hu Qiong Li Song-Nan Gong Xiao-Jie Zou Jia-Yue Xu Hai-Feng Ying Lan Zheng |
| author_sort | Chao Hu |
| collection | DOAJ |
| description | Gastric cancer (GC), a life-threatening malignancy with profound global health impacts, remains a cardinal focus of biomedical research. Recently, astragaloside IV (AS-IV), a bioactive triterpenoid saponin derived from Astragalus mongholicus Bunge, has garnered substantial attention for its multifaceted anticancer properties in preclinical investigations. This review systematically synthesizes current evidence on the molecular mechanisms underlying AS-IV’s inhibitory effects against GC, encompassing programmed cell death pathways (apoptosis, autophagy, pyroptosis, ferroptosis), tumor angiogenesis, tumor microenvironment modulation, Helicobacter pylori and inflammatory signaling networks. Many studies demonstrate that AS-IV can inhibit the development of GC through multi-target and multi-pathway mechanisms, making it a well-deserved nemesis of GC. Notably, although AS-IV has emerged as a potential candidate for GC therapy, it suffers from problems such as single research model, unclear toxic and side effects, and poor bioavailability. These seriously hinder the efficiency of AS-IV in the treatment of GC. In the future, we can design and implement a series of in vivo and in vitro experiments to further explore and clarify the mechanism of action of AS-IV in the treatment of GC. It is encouraged to carry out a number of high-quality clinical controlled studies to further prove the effectiveness and safety of AS-IV. In addition, we can also use emerging technologies (such as nanotechnology) to improve the bioavailability of AS-IV, bringing more hope to GC patients. |
| format | Article |
| id | doaj-art-2f3c145db50a46c1a45d96a1bad103b6 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-2f3c145db50a46c1a45d96a1bad103b62025-08-20T03:28:04ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-07-011610.3389/fphar.2025.16363411636341Astragaloside IV: a potential nemesis for gastric cancerChao Hu0Qiong Li1Song-Nan Gong2Xiao-Jie Zou3Jia-Yue Xu4Hai-Feng Ying5Lan Zheng6Department of Traditional Chinese Medicine, Loujiang New City Hospital of Taicang (Taicang Branch of Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine), Suzhou, ChinaDepartment of Hepatology, Yueyang Hospital of Integrated Traditional Chinese and Westen Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Gastroenterology, Loujiang New City Hospital of Taicang (Taicang Branch of Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine), Suzhou, ChinaDepartment of Public Health, Loujiang New City Hospital of Taicang (Taicang Branch of Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine), Suzhou, ChinaDepartment of Traditional Chinese Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Traditional Chinese Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Traditional Chinese Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaGastric cancer (GC), a life-threatening malignancy with profound global health impacts, remains a cardinal focus of biomedical research. Recently, astragaloside IV (AS-IV), a bioactive triterpenoid saponin derived from Astragalus mongholicus Bunge, has garnered substantial attention for its multifaceted anticancer properties in preclinical investigations. This review systematically synthesizes current evidence on the molecular mechanisms underlying AS-IV’s inhibitory effects against GC, encompassing programmed cell death pathways (apoptosis, autophagy, pyroptosis, ferroptosis), tumor angiogenesis, tumor microenvironment modulation, Helicobacter pylori and inflammatory signaling networks. Many studies demonstrate that AS-IV can inhibit the development of GC through multi-target and multi-pathway mechanisms, making it a well-deserved nemesis of GC. Notably, although AS-IV has emerged as a potential candidate for GC therapy, it suffers from problems such as single research model, unclear toxic and side effects, and poor bioavailability. These seriously hinder the efficiency of AS-IV in the treatment of GC. In the future, we can design and implement a series of in vivo and in vitro experiments to further explore and clarify the mechanism of action of AS-IV in the treatment of GC. It is encouraged to carry out a number of high-quality clinical controlled studies to further prove the effectiveness and safety of AS-IV. In addition, we can also use emerging technologies (such as nanotechnology) to improve the bioavailability of AS-IV, bringing more hope to GC patients.https://www.frontiersin.org/articles/10.3389/fphar.2025.1636341/fullgastric cancerastragaloside IVapoptosismechanismsreview |
| spellingShingle | Chao Hu Qiong Li Song-Nan Gong Xiao-Jie Zou Jia-Yue Xu Hai-Feng Ying Lan Zheng Astragaloside IV: a potential nemesis for gastric cancer Frontiers in Pharmacology gastric cancer astragaloside IV apoptosis mechanisms review |
| title | Astragaloside IV: a potential nemesis for gastric cancer |
| title_full | Astragaloside IV: a potential nemesis for gastric cancer |
| title_fullStr | Astragaloside IV: a potential nemesis for gastric cancer |
| title_full_unstemmed | Astragaloside IV: a potential nemesis for gastric cancer |
| title_short | Astragaloside IV: a potential nemesis for gastric cancer |
| title_sort | astragaloside iv a potential nemesis for gastric cancer |
| topic | gastric cancer astragaloside IV apoptosis mechanisms review |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1636341/full |
| work_keys_str_mv | AT chaohu astragalosideivapotentialnemesisforgastriccancer AT qiongli astragalosideivapotentialnemesisforgastriccancer AT songnangong astragalosideivapotentialnemesisforgastriccancer AT xiaojiezou astragalosideivapotentialnemesisforgastriccancer AT jiayuexu astragalosideivapotentialnemesisforgastriccancer AT haifengying astragalosideivapotentialnemesisforgastriccancer AT lanzheng astragalosideivapotentialnemesisforgastriccancer |